Browsing Tag
Mead Johnson
3 posts
Abbott pays $670m to settle Gill and 2,000 NEC claims, $70m above one judgment
Abbott has agreed to pay about $670 million to resolve the Gill verdict and claims involving roughly 2,000 other infants, substantially reducing one litigation block while leaving a much larger pool of NEC claims outstanding.
Why Abbott Laboratories (NYSE: ABT) faces more than a legal bill after $70m Chicago baby formula ruling
Abbott was ordered to pay $70 million in a Chicago baby formula case. Read what the NEC verdict could mean for litigation risk, strategy, and ABT stock.
Reckitt Benckiser to sell 92% stake in Chinese infant formula business for $1.3bn
Reckitt Benckiser Group has agreed to divest 92% stake in Infant Formula and Child Nutrition business in China…